KYTX Earnings Date & History
Kyverna Therapeutics Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 4:07 PM ET
Kyverna Therapeutics Inc
Biotechnology
- Next earnings date
- Tuesday, November 10, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.75
- Revenue estimate
- $0
KYTX earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Tuesday, May 12, 2026 | Q1 2026 | $-0.77 | $-0.66 | +13.9% | $0 |
| Thursday, March 26, 2026 | Q4 2025 | $-0.88 | $-0.80 | +8.6% | $0 |
| Wednesday, November 12, 2025 | Q3 2025 | $-0.99 | $-0.85 | +14.2% | $0 |
| Tuesday, August 12, 2025 | Q2 2025 | $-1.06 | $-0.97 | +8.9% | $0 |
What the market is watching in KYTX's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next KYTX earnings date?
- Kyverna Therapeutics Inc is scheduled to report on Tuesday, November 10, 2026 (Time TBD). Dates can change until the company confirms them.
- Does KYTX report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for KYTX?
- Consensus EPS for the upcoming quarter is $-0.75, on revenue of $0.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
KYTX earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.